Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 132-1173 Dundas Street East TORONTO ON M4M 3P1 |
Tel: | N/A |
Website: | https://thermabright.com |
IR: | See website |
Key People | ||
Rob Fia President, Chief Executive Officer, Director | Eric Myung Chief Financial Officer |
Business Overview |
Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation. |
Financial Overview |
For the six months ended 31 January 2024, Therma Bright Inc revenues increased 15% to C$14K. Net loss decreased 78% to C$257K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 80% to C$211K (expense), Research and development decrease from C$52K (expense) to C$0K. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $3.08M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.03M as of Jan 31, 2024 |
EBITDA (TTM): | -$2.71M as of Jan 31, 2024 |
Net annual income (TTM): | -$2.88M as of Jan 31, 2024 |
Free cash flow (TTM): | -$0.90M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $0.08M as of Jan 31, 2024 |
Shares outstanding: | 315,915,855 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |